Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity and Safety of Freeze-Dried Human Rabies Vaccine (Vero Cell) in Patients Infected With Human Immunodeficiency Virus (HIV)

NCT07932132 is registered in ClinicalTrials.gov with Liaoning Chengda Biotechnology CO., LTD as lead sponsor.

NCT NCT07932132 Recruiting Phase 4 160 participants (estimated) Started 2026 2 sites

Follow this trial by email Email me the PDF

Get the NCT07932132 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Summary

Recruiting, started August 2026. Interventional study, Phase 4, 160 participants (estimated). Lead sponsor Liaoning Chengda Biotechnology CO., LTD; China. Primary measures: Seroconversion rate and geometric mean concentration (GMC) of rabies virus neutralizing antibodies at 14...; Incidence of adverse events after vaccination.

How it compares

12 similar trials: same condition (Rabies) and phase

Enrollment

This trial
160
Middle half
102 to 278
Median
185
Trials with a value
12

Months from start to completion

This trial
22.7
Middle half
9.6 to 24.8
Median
16.4
Trials with a value
12

Sites

This trial
2
Middle half
1 to 2
Median
1
Trials with a value
11
Posted results or a linked paper 50% 6 of 12 similar trials; this trial: no

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity and Safety of Freeze-Dried Human Rabies Vaccine (Vero Cell) in Patients Infected With Human Immunodeficiency Virus (HIV)
Lead sponsor
Liaoning Chengda Biotechnology CO., LTD
Phase
Phase 4
Overall status
Recruiting
Start date
August 8, 2026
Completion date
June 30, 2028
Enrollment
160 (estimated)
Sites
2

Conditions

MeSH condition names; the registry's own terms follow.

Who could take part, where it ran, who ran it

As filed in ClinicalTrials.gov.

Sex
All
Minimum age
18 Years
Maximum age
60 Years
Healthy volunteers
No
Study type
Interventional
Sites
2
Countries
China
Lead sponsor
Liaoning Chengda Biotechnology CO., LTD

Arms

As registered; 4 arms.

Registered arms
Arm Type Interventions
Zagreb regimen (CD4+ T cell count ≥350 cells/mm³) Experimental Rabies Vaccine (Vero Cell) for Human Use, Freeze-dried
Show registry wording

Eligible HIV-infected participants on stable antiretroviral therapy and with a baseline CD4+ T cell count ≥350 cells/mm³ will receive 2 doses of rabies vaccine on day 0, 1 dose on day 7, and 1 dose on day 21, for a total of 4 doses.

Essen regimen (CD4+ T cell count ≥350 cells/mm³) Experimental Rabies Vaccine (Vero Cell) for Human Use, Freeze-dried
Show registry wording

Eligible HIV-infected participants on stable antiretroviral therapy and with a baseline CD4+ T cell count ≥350 cells/mm³ will receive 1 dose of rabies vaccine on day 0, 3, 7, 14, and 28, for a total of 5 doses.

Zagreb regimen (CD4+ T cell count <350 cells/mm³) Experimental Rabies Vaccine (Vero Cell) for Human Use, Freeze-dried
Show registry wording

Eligible HIV-infected participants on stable antiretroviral therapy and with a baseline CD4+ T cell count \<350 cells/mm³ will receive 2 doses of rabies vaccine on day 0, 1 dose on day 7 and 1 dose on day 21, for a total of 4 doses.

Essen regimen (CD4+ T cell count <350 cells/mm³) Experimental Rabies Vaccine (Vero Cell) for Human Use, Freeze-dried
Show registry wording

Eligible HIV-infected participants on stable antiretroviral therapy and with a baseline CD4+ T cell count \<350 cells/mm³ will receive 1 dose of rabies vaccine on day 0, 3, 7, 14, and 28, for a total of 5 doses.

Primary endpoints

Registered primary outcome measures; 2 primary.

Registered primary endpoints
Measure Time frame
Seroconversion rate and geometric mean concentration (GMC) of rabies virus neutralizing antibodies at 14 days after completion of the full vaccination course 14 days after completion of the full vaccination course
Show registry wording

Seroconversion rate and GMC of rabies virus neutralizing antibodies among HIV-infected participants who are seronegative at baseline (Day 0). Seroconversion is defined as a rabies virus neutralizing antibody titer ≥0.5 IU/mL. Rabies virus neutralizing antibodies will be assessed by the rapid fluorescent focus inhibition test (RFFIT).

Incidence of adverse events after vaccination 30 minutes, 0-7 days, and 8-14 days after each vaccine dose
Show registry wording

Incidence of immediate local and systemic adverse events recorded within 30 minutes after each vaccination; incidence of solicited local and systemic adverse events collected 0-7 days after each dose; incidence of unsolicited adverse events collected 8-14 days after each dose. Adverse events are defined as any untoward medical occurrence in a participant administered vaccine, not necessarily having a causal relationship with vaccination.

Lead sponsor's other trials

Liaoning Chengda Biotechnology CO., LTD, most recent start first.

Similar trials

Same condition (Rabies) and phase, most recent start first.